- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04104243
Power-Up: An Effectiveness Trial of the Diabetes Prevention Program (Power-Up)
Power-Up: An Effectiveness Trial of the Diabetes Prevention Program Tailored for Men
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The rising epidemic of type 2 diabetes is a major cause of disability and death that disproportionately affects men. Compared to women, men have much worse health and higher death rates for several chronic conditions, including diabetes. The National Diabetes Prevention Program (NDPP) has been shown to help decrease the chances of developing type 2 diabetes. The NDPP has shown the value of lifestyle change for weight loss and diabetes prevention. The Power-Up study is being done because although the evidence points to the effectiveness of the Diabetes Prevention Program (DPP), men are less likely to be engaged or participate in DPP.
The Power-up study was designed to see whether a DPP tailored for men can help improve engagement, participation, and results for men. Participants will be randomized to either undergo the Power-Up or standard NDPP classes. An assessment of whether a DPP created for men will increase participation in the program and decrease the risk for diabetes as compared to the standard NDPP. Power-Up is designed to Aim 1) Assess the effect of Power-Up vs. standard care NDPP on percent weight loss among men at risk for diabetes; Aim 2) Compare engagement of minority men at risk for diabetes in Power-Up vs. standard care NDPP; and Aim 3) Evaluate the Reach, Effectiveness, Adoption, Implementation, and Costs of Power-Up using the RE-AIM framework. The Power-Up intervention is tailored to the needs and preferences of men and uses: a) men coaches; b) men-only groups; c) messaging tailored to be appreciated and motivational to men; d) adapted content that highlights issues relevant to men.
There are 22-28 classes over the course of 12 months for both Power-Up and standard NDPP. The classes are split into two phases which are called the core and the maintenance phases. The core phase of the program will consist of at least 16 classes over the first 6 months. After the core, participants will attend maintenance classes over the next 6 months. Participants will be asked over the course of the 12 months to complete surveys at three different times before, during, and after completing the classes.
The hypothesis is that men randomized to Power-Up will achieve significantly greater weight loss (% weight loss from baseline) at 16 weeks and 1 year than men randomized to the standard care, mixed-gender NDPP group (Aim 1). Evaluation of engagement and retention for Aim 2 is based on attendance records for Power-Up and NDPP sessions electronically collected by trained coaches and monitored by study staff. The standards will be followed for NDPP evaluation where engagement is defined as equal or greater than 4 core sessions attended and retention is defined as equal or greater than 9 sessions attended. There will be a collection of quantitative and qualitative data that will be rigorously evaluated: the reach of our recruitment, broader patient-important indicators of effectiveness, adoption at the practice level, and implementation of the intervention (Aim 3).
Enrollment consists of 300 participants through our health system partners. Men will be randomized 1:1 to either the Power-Up intervention arm or referred to the standard NDPP at their clinic site. Consistent with current Centers for Disease Control and Prevention (CDC) standards and current NDPP practices of our health system partners, telephone make-up sessions will be offered by coaches in both conditions to men who miss in-person sessions.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
The Bronx, New York, United States, 10461
- Albert Einstein College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years old
- Most recent HbA1c: 5.7%-6.4% (within last year) or Diabetes Risk Score >= 5
- Most recent BMI ≥ 25 (within last 6 months)
- Access to a device that can join sessions virtually either through a virtual conferencing application
- Have valid address and telephone contact information
- Have no plans to change their health system/primary care provider or move from their current, NYC area, address in the next year
Exclusion Criteria:
- Not physically able or willing to attend virtual, group-based sessions
- Unable to provide informed consent by telephone
- Unable or unwilling to complete baseline telephone surveys or follow-up surveys in English or Spanish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Power-Up
Participants randomized to this arm will undergo 16 classes tailored for men, that discuss food choices, physical activity, and managing stress over 6 months, which are called the core, and 6 classes over the following 6 months, which is called the maintenance phase.
|
Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
|
|
No Intervention: Standard NDPP (National Diabetes Prevention Program)
Participants randomized to this arm will undergo 16 mixed gender classes that discuss food choices, physical activity, and managing stress over 6 months which are called the core and 6 classes over the following 6 months which is called the maintenance phase.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Weight Change Through 16 Sessions
Time Frame: Up to 6 months, after the delivery of the 16th session (end of the core phase)
|
The percent weight change through 16 sessions was compared.
Mean percent weight change for each arm for all intent-to-treat (ITT) participants (i.e.. attended >=0 sessions), as well as those who were considered "Engaged" (i.e., attended >=4 sessions) or "Retained" (i.e., attended >=9 sessions), through 16 scheduled sessions, was determined.
All data is crude and unadjusted with no imputation.
|
Up to 6 months, after the delivery of the 16th session (end of the core phase)
|
|
Percent Weight Change Through the 12 Month Trial
Time Frame: 12 Months (At end of maintenance phase)
|
The percent weight change through 12 months was compared.
Mean percent weight change for each arm for all intent-to-treat (ITT) participants (i.e., attended >=0 sessions), as well as those who were considered "Engaged" (i.e., attended >=4 sessions) or "Retained" (i.e., attended >=9 sessions), through 12 months, was determined.
All data is crude and unadjusted with no imputation.
|
12 Months (At end of maintenance phase)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Engagement of Men in Power-Up vs Standard National Diabetes Prevention Program
Time Frame: 6 Months (At end of the core phase)
|
Engagement of men at risk for diabetes in Power-Up vs. Standard NDPP was compared based on the number of sessions attended.
Engagement is characterized as attending >= 4 sessions.
Counts and percentages of participants who attended at least 4 sessions in the first six months of the workshops are summarized by study arm.
This is halfway through the entire trial.
|
6 Months (At end of the core phase)
|
|
Retention of Men in Power-Up vs Standard National Diabetes Prevention Program
Time Frame: 12 Months (At end of the maintenance phase)
|
Retention of men at risk for diabetes in Power-Up vs. Standard NDPP was compared based on the number of sessions attended.
Participants are defined as "retained" if they attended >=9 more sessions.
It is expected that men randomized to the Power-Up sessions will have greater engagement and retention rates than men randomized to standard care and referred to mixed-gender NDPP classes.
Counts and percentages of participants who attended at least 9 sessions through the 12 months of workshops are summarized by study arm.
|
12 Months (At end of the maintenance phase)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Earle Chambers, PhD, Albert Einstein College of Medicine
Publications and helpful links
General Publications
- Realmuto L, Kamler A, Weiss L, Gary-Webb TL, Hodge ME, Pagan JA, Walker EA. Power Up for Health-Participants' Perspectives on an Adaptation of the National Diabetes Prevention Program to Engage Men. Am J Mens Health. 2018 Jul;12(4):981-988. doi: 10.1177/1557988318758786. Epub 2018 Mar 15.
- Walker EA, Weiss L, Gary-Webb TL, Realmuto L, Kamler A, Ravenell J, Tejeda C, Lukin J, Schechter CB. Power Up for Health: Pilot Study Outcomes of a Diabetes Prevention Program for Men from Disadvantaged Neighborhoods. Am J Mens Health. 2018 Jul;12(4):989-997. doi: 10.1177/1557988318758787. Epub 2018 Mar 15.
- Gary-Webb TL, Walker EA, Realmuto L, Kamler A, Lukin J, Tyson W, Carrasquillo O, Weiss L. Translation of the National Diabetes Prevention Program to Engage Men in Disadvantaged Neighborhoods in New York City: A Description of Power Up for Health. Am J Mens Health. 2018 Jul;12(4):998-1006. doi: 10.1177/1557988318758788. Epub 2018 Mar 15.
- Chambers EC, Walker EA, Schechter C, Gil E, Herbert T, Diaz K, Gonzalez J. Virtual Diabetes Prevention Program Tailored to Increase Participation of Black and Latino Men: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Jun 24;14:e64405. doi: 10.2196/64405.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-10343 (Other Identifier: Einstein - IRB ID)
- 5R01DK121896-04 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
University of PennsylvaniaNational Institute on Aging (NIA); American Heart AssociationRecruitingType 2 Diabetes Mellitus | Type 2 Diabetes | Type II Diabetes Mellitus | Pre-diabetes | Pre-diabetic | Type II Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2DM) | Pre-diabetic StateUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
Clinical Trials on Men-Tailored DPP (Power-Up)
-
University of Missouri, Kansas CityChildren's Mercy Hospital Kansas City; University of Massachusetts, Amherst; University... and other collaboratorsRecruitingPreDiabetes | Overweight and ObesityUnited States
-
University of California, Los AngelesAmerican Diabetes AssociationRecruitingType 2 Diabetes | PrediabetesUnited States
-
University College, LondonAnna Freud National Centre for Children and Families; MindTech Healthcare Technology... and other collaboratorsUnknown
-
Rush University Medical CenterNational Institute of Mental Health (NIMH); University of Illinois at Chicago; Planned Parenthood of IllinoisNot yet recruitingHIV | Prevention | PrEP Uptake
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingPre DiabetesUnited States
-
Vejle HospitalCompleted
-
University of California, Los AngelesAmerican Diabetes AssociationCompletedDiabetes Mellitus, Type 2 | PreDiabetesUnited States
-
Lovisenberg Diakonale HospitalUniversity of OsloRecruiting
-
Harran UniversityNot yet recruitingDiastasis Recti Abdominis Postpartum Period Cesarean Section Sexual Dysfunction, Physiological Pelvic Floor Muscle TrainingTurkey (Türkiye)
-
Tianjin Medical University Cancer Institute and...Tianjin Medical University General Hospital; Tianjin Third Central Hospital; Tianjin... and other collaboratorsEnrolling by invitationBreast Cancer | Depression Anxiety Disorder | CDK4/6 InhibitorsChina